FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137375314> ?p ?o ?g. }

• W3137375314 endingPage "2119" @default.
• W3137375314 startingPage "2109" @default.
• W3137375314 abstract "The development of highly effective targeted therapies has led to a new treatment paradigm in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Despite these advances, many patients will eventually require alternative treatment strategies due to the emergence of tolerability issues or resistance to these novel agents. Duvelisib is a first-in-class, potent oral agent with dual inhibitor activity against the δ and γ isoforms of phosphoinositide 3-kinase (PI3Kδ and PI3Kγ), which are specific to the hematopoietic system. Dysregulation of the PI3K/PTEN/AKT/mTOR pathway has been implicated in cancer cell growth, survival and metabolism and has been the subject of cancer drug development in recent years. Duvelisib demonstrated activity in CLL/SLL in early trials, leading to further evaluation in the Phase 3 DUO trial that compared duvelisib against ofatumumab in patients with relapsed/refractory CLL/SLL. This trial led to the Food and Drug Administration (FDA) approval for the treatment of adult patients with CLL/SLL after at least two prior lines of therapy. The major reason for therapy discontinuation is the development of serious adverse events, which include severe infections and diarrhea/colitis, precluding its widespread use. Ongoing clinical trials are evaluating duvelisib in combination strategies and with alternate dosing schedules in patients with CLL/SLL. With close monitoring, duvelisib can be a promising drug for the treatment of patients with relapsed or refractory CLL/SLL. This review summarizes the relevant clinical data from recent clinical advances in CLL and aims to interpret the duvelisib trials while exploring strategies to improve its use and adverse event management in the era of novel targeted agents." @default.
• W3137375314 created "2021-03-29" @default.
• W3137375314 creator A5060545788 @default.
• W3137375314 creator A5075229974 @default.
• W3137375314 date "2021-03-01" @default.
• W3137375314 modified "2023-10-14" @default.
• W3137375314 title "Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib" @default.
• W3137375314 cites W1243376384 @default.
• W3137375314 cites W1527161131 @default.
• W3137375314 cites W1963866495 @default.
• W3137375314 cites W1977267072 @default.
• W3137375314 cites W1979918288 @default.
• W3137375314 cites W1994709165 @default.
• W3137375314 cites W2001850157 @default.
• W3137375314 cites W2023976667 @default.
• W3137375314 cites W2026602389 @default.
• W3137375314 cites W2027971058 @default.
• W3137375314 cites W2066564017 @default.
• W3137375314 cites W2071549499 @default.
• W3137375314 cites W2084952484 @default.
• W3137375314 cites W2108206643 @default.
• W3137375314 cites W2113895281 @default.
• W3137375314 cites W2124920464 @default.
• W3137375314 cites W2125134816 @default.
• W3137375314 cites W2134797116 @default.
• W3137375314 cites W2135216058 @default.
• W3137375314 cites W2169450835 @default.
• W3137375314 cites W2233614027 @default.
• W3137375314 cites W2295348655 @default.
• W3137375314 cites W2310716991 @default.
• W3137375314 cites W2318933236 @default.
• W3137375314 cites W2337485820 @default.
• W3137375314 cites W2369297677 @default.
• W3137375314 cites W2399409583 @default.
• W3137375314 cites W2412117720 @default.
• W3137375314 cites W2519500141 @default.
• W3137375314 cites W2558110451 @default.
• W3137375314 cites W2563723939 @default.
• W3137375314 cites W2604313146 @default.
• W3137375314 cites W2739393823 @default.
• W3137375314 cites W2760227417 @default.
• W3137375314 cites W2775670706 @default.
• W3137375314 cites W2790385276 @default.
• W3137375314 cites W2792666902 @default.
• W3137375314 cites W2885065879 @default.
• W3137375314 cites W2886908325 @default.
• W3137375314 cites W2895287765 @default.
• W3137375314 cites W2902706178 @default.
• W3137375314 cites W2907555512 @default.
• W3137375314 cites W2908732636 @default.
• W3137375314 cites W2914691947 @default.
• W3137375314 cites W2915350842 @default.
• W3137375314 cites W2936399310 @default.
• W3137375314 cites W2942506175 @default.
• W3137375314 cites W2948436219 @default.
• W3137375314 cites W2966190920 @default.
• W3137375314 cites W2973195462 @default.
• W3137375314 cites W2976015310 @default.
• W3137375314 cites W2987552010 @default.
• W3137375314 cites W2988261100 @default.
• W3137375314 cites W3012414877 @default.
• W3137375314 cites W3013722594 @default.
• W3137375314 cites W3016218657 @default.
• W3137375314 cites W3082899459 @default.
• W3137375314 cites W3110301988 @default.
• W3137375314 doi "https://doi.org/10.2147/ott.s189032" @default.
• W3137375314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8006759" @default.
• W3137375314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33790574" @default.
• W3137375314 hasPublicationYear "2021" @default.
• W3137375314 type Work @default.
• W3137375314 sameAs 3137375314 @default.
• W3137375314 citedByCount "9" @default.
• W3137375314 countsByYear W31373753142021 @default.
• W3137375314 countsByYear W31373753142022 @default.
• W3137375314 countsByYear W31373753142023 @default.
• W3137375314 crossrefType "journal-article" @default.
• W3137375314 hasAuthorship W3137375314A5060545788 @default.
• W3137375314 hasAuthorship W3137375314A5075229974 @default.
• W3137375314 hasBestOaLocation W31373753141 @default.
• W3137375314 hasConcept C126322002 @default.
• W3137375314 hasConcept C138885662 @default.
• W3137375314 hasConcept C16005928 @default.
• W3137375314 hasConcept C177713679 @default.
• W3137375314 hasConcept C199033989 @default.
• W3137375314 hasConcept C2777938653 @default.
• W3137375314 hasConcept C2778461978 @default.
• W3137375314 hasConcept C2779338263 @default.
• W3137375314 hasConcept C3020000205 @default.
• W3137375314 hasConcept C41895202 @default.
• W3137375314 hasConcept C502942594 @default.
• W3137375314 hasConcept C71924100 @default.
• W3137375314 hasConceptScore W3137375314C126322002 @default.
• W3137375314 hasConceptScore W3137375314C138885662 @default.
• W3137375314 hasConceptScore W3137375314C16005928 @default.
• W3137375314 hasConceptScore W3137375314C177713679 @default.
• W3137375314 hasConceptScore W3137375314C199033989 @default.
• W3137375314 hasConceptScore W3137375314C2777938653 @default.
• W3137375314 hasConceptScore W3137375314C2778461978 @default.

• next